

# OPTIMA HEALTH PLAN

## MEDICAL PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

**Directions:** The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-844-668-1550**. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If information provided is not complete, correct, or legible, authorization can be delayed.**

**For Medicare Members:** Medicare Coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/overview-and-quick-search.aspx>. Additional indications may be covered at the discretion of the health plan.

**Drug Requested:** Omisirge® (omidubicel-only) (J3590) (Medical)

**MEMBER & PRESCRIBER INFORMATION:** Authorization may be delayed if incomplete.

Member Name: \_\_\_\_\_

Member Optima #: \_\_\_\_\_ Date of Birth: \_\_\_\_\_

Prescriber Name: \_\_\_\_\_

Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_

Office Contact Name: \_\_\_\_\_

Phone Number: \_\_\_\_\_ Fax Number: \_\_\_\_\_

DEA OR NPI #: \_\_\_\_\_

**DRUG INFORMATION:** Authorization may be delayed if incomplete.

Drug Form/Strength: \_\_\_\_\_

Dosing Schedule: \_\_\_\_\_ Length of Therapy: \_\_\_\_\_

Diagnosis: \_\_\_\_\_ ICD Code, if applicable: \_\_\_\_\_

Weight: \_\_\_\_\_ Date: \_\_\_\_\_

☐ Standard Review. In checking this box, the timeframe does not jeopardize the life or health of the member or the member's ability to regain maximum function and would not subject the member to severe pain.

**A. Quantity Limit (max daily dose) [NDC Unit]:**

- Omisirge, 1 kit, NDC: 73441-0800-04, a single dose consisting of:
  - Cultured Fraction (CF): a minimum of  $8.0 \times 10^8$  total viable cells of which a minimum of 8.7% is CD34+ cells and a minimum of  $9.2 \times 10^7$  CD34+ cells
  - Non-cultured Fraction (NF): a minimum of  $4.0 \times 10^8$  total viable cells with a minimum of  $2.4 \times 10^7$  CD3+ cells

**B. Max Units (per dose and over time):**

- 1 dose only (single-use culture containing at least  $12 \times 10^8$  live cells, which include CD34+ and CD3+ cells)

(Continued on next page)

**CLINICAL CRITERIA:** Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

**Authorization Criteria: One-Time Authorization. Coverage may NOT be renewed**

- ☐ Member is 12 years of age or older
- ☐ Provider is a specialist an oncologist, and/or transplant specialty
- ☐ Member is eligible for allogeneic hematopoietic stem cell transplant (allo-HSCT) and has **NOT** received a prior allo-HSCT (**documentation of medical treatment history verifying prior lines of therapy and/or pre-transplant debulking therapy must be submitted**)
- ☐ Member's has a diagnosis of a high-risk hematologic malignancy and is planned for an umbilical cord blood transplantation (UCBT) following myeloablative conditioning
- ☐ Requested medication will be used to reduce the time to neutrophil recovery and incidence of infection
- ☐ Member will receive prophylactic and supportive therapies for prevention or treatment of transplant complications (e.g., GVHD, infections) according to institutional guidelines
- ☐ Member does **NOT** have a readily available matched related donor (MRD), matched unrelated donor (MUD), mismatched (7/8 matched) unrelated donor (MMUD), or haploidentical (half HLA-matched) related donor
- ☐ Member does **NOT** have a known allergy or hypersensitivity to any of the following: dimethyl sulfoxide (DMSO), dextran 40, gentamicin, human serum albumin or bovine material
- ☐ Member does **NOT** have a clinically significant active/uncontrolled systemic infection
- ☐ Member does **NOT** have active/symptoms of central nervous system (CNS) disease

**Reauthorization: Coverage may NOT be renewed**

**Medication being provided by:** Please check applicable box below.

- ☐ Location/site of drug administration: \_\_\_\_\_  
NPI or DEA # of administering location: \_\_\_\_\_

**OR**

- ☐ Specialty Pharmacy – Proprium Rx

***\*\*Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.\*\****

***\*Previous therapies will be verified through pharmacy paid claims or submitted chart notes.\****